[CAS NO. 92134-98-0] Fosphenytoin disodium
PRODUCTS SPECIFICATIONS [92134-98-0]
DESCRIPTION [92134-98-0]
Overview
| MDL | MFCD00948765 |
|---|---|
| Molecular Weight | 406.24 |
| Molecular Formula | C16H13N2Na2O6P |
| SMILES | O=C1N(COP(O[Na])(O[Na])=O)C(C(C2=CC=CC=C2)(C3=CC=CC=C3)N1)=O |
Summary
Fosphenytoin sodium is a phenytoin prodrug with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
In Vivo
Fosphenytoin is an effective neuroprotectant against ischemia-induced damage. In fosphenytoin (30 mg/kg, i.m.)-treated rat 5 min after ischemia episode, hippocampal CA1 pyramidal neurons remain at near control level (13.90 +/- 0.92), however, GFAP staining iss not significantly changed [1] . In fosphenytoin (84 mg/kg)-treated rat, the relative bioavailability of fosphenytoin is 83%. In fully kindled female Wistar rats, fosphenytoin dose-dependently increases the focal seizure (afterdischarge) threshold. Seizure severity and duration at threshold are reduced only after the highest does of fosphenytoin tested (84 mg/kg) [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01110187 | University of Alabama at Birmingham|UCB Pharma |
Traumatic Brain Injury
|
May 2010 | Not Applicable |
| NCT01960075 | University of Virginia|University of Michigan|Medical University of South Carolina|Children´s National Research Institute|University of Minnesota|National Institute of Neurological Disorders and Stroke (NINDS) |
Benzodiazepine Refractory Status Epilepticus
|
October 2015 | Phase 3 |
| NCT03712254 | Danish Headache Center |
Trigeminal Neuralgia
|
November 1, 2018 | |
| NCT00510783 | Emory University|UCB Pharma |
Tonic-clonic Seizure
|
July 2007 | Phase 4 |
| NCT01870024 | Assistance Publique - Hôpitaux de Paris |
Status Epilepticus|Epilepsy
|
June 26, 2013 | Phase 3 |
| NCT00908453 | Nobelpharma |
Epilepsy
|
May 2009 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : ≥ 100 mg/mL ( 246.16 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4616 mL | 12.3080 mL | 24.6160 mL |
| 5 mM | 0.4923 mL | 2.4616 mL | 4.9232 mL |
| 10 mM | 0.2462 mL | 1.2308 mL | 2.4616 mL |
References
- [1] Chan SA, et al. Fosphenytoin reduces hippocampal neuronal damage in rat following transient global ischemia. Acta Neurochir (Wien). 1998;140(2):175-80.
- [2] Loscher W, et al. Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin. Epilepsy Res. 1998 Mar;30(1):69-76.
Synonyms
